ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma
Ossia M. Eichhoff(University of Zurich), Mitchell P. Levesque(Duke University)
Cited by 0
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Predictors of responses to immune checkpoint blockade in advanced melanoma
|Nature Communications|2017|201
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
|Cancer Cell|2021|154
Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma
|Cancer Research|2019|53